Zum Inhalt
Erschienen in:

13.07.2020 | short review

San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor 2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)

verfasst von: Clemens Dormann, M.D.

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Summary

At the 2019 San Antonio Breast Cancer Symposium, new data on the management of heavily pretreated human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer were discussed. The phase 3 HER2CLIMB and the phase 2 DESTINY-Breast01 trials investigating tucatinib and trastuzumab deruxtecan, respectively, have met their primary endpoints.
In an early disease setting, four studies investigated whether image-guided biopsies could identify patients with a pathologic complete response (pCR) to neoadjuvant chemotherapy, thus allowing safe omission of surgery. As residual disease was missed in a significant number of cases, these trials could not confirm data from smaller previous studies.
Literatur
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Metadaten
Titel
San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor 2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)
verfasst von
Clemens Dormann, M.D.
Publikationsdatum
13.07.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00632-x